New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
10:00 EDTEPR, XUE, LPL, CBL, BCRX, FWLT, ARW, AWR, HSPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Arrow Electronics (ARW) downgraded to Underperform from Outperform at CLSA... CBL & Associates (CBL) downgraded to Neutral from Buy at Goldman... Entertainment Properties (EPR) downgraded to Neutral from Buy at Goldman... Foster Wheeler (FWLT) downgraded to Neutral from Buy at Lazard Capital... Hospira (HSP) downgraded to Sell from Neutral at Goldman... LG Display (LPL) downgraded to Sell from Hold at Topeka... BioCryst (BCRX) downgraded to Hold from Buy at Noble Financial... Xueda Education (XUE) downgraded to Sell from Buy at Goldman... American States Water (AWR) downgraded to Neutral from Buy at Ladenburg.
News For ARW;CBL;EPR;FWLT;LPL;HSP;BCRX;XUE;AWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
16:11 EDTEPREPR Properties says development partner selected for NY casino
Subscribe for More Information
December 16, 2014
07:02 EDTEPREPR Properties initiated with an Outperform at FBR Capital
Subscribe for More Information
December 15, 2014
07:17 EDTBCRXBioCryst initiates Phase 1 clinical trial of BCX4430
BioCryst Pharmaceuticals announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate intramuscular, or I.M., administration of BCX4430 in healthy volunteers. BCX4430 is being developed as a potential treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430 administered via I.M. injection in healthy subjects. In part one of the study, subjects will receive a single dose of BCX4430; in part two of the study, subjects will receive BCX4430 for seven days. Up to six single-dose cohorts and four multiple-dose cohorts will be evaluated, with a total of up to 88 volunteers participating.
December 12, 2014
08:01 EDTARWArrow Electronics announces additional $200M share repurchase program
Arrow Electronics announced the approval by the companyís board of directors of the repurchase of up to an additional $200M of common stock through a share repurchase program. The company has spent approximately $1.2B on share repurchases since the beginning of 2010 and this action will permit the company to continue repurchasing shares of its common stock as market and business conditions warrant.
December 11, 2014
07:13 EDTHSPDanone to discuss whether to keep or sell medical nutrition unit, Reuters says
According to a source, Danone (DANOY) will hold a board meeting today to discuss whether to keep or sell its medical nutrition business, Reuters reports. Previous reports said Danone's board would decide whether to sell the unit to Hospira (HSP) or Fresenius (FMS), with Fresenius as the possible front-runner to enter exclusive talks. Reference Link
December 9, 2014
13:08 EDTHSPMerck may have paid $2B-$3B too much for Cubist, analyst says
Subscribe for More Information
08:23 EDTHSPMerck has 'no way out' of Cubist deal after court decision, says Leerink
Subscribe for More Information
08:12 EDTHSPMerck still sees Cubist acquisition neutral to modestly accretive to 2015 EPS
Merck (MRK) issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist (CBST) will create strong fundamental value for Merckís shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1B of revenue to its 2015 base, with strong growth potential thereafter. The courtís decision does not change Merckís expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a percentage basis to non-GAAP EPS in 2016, and will continue to be accretive thereafter.
December 8, 2014
19:00 EDTHSPCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:24 EDTHSPOn The Fly: After Hours Movers
Subscribe for More Information
18:00 EDTHSPCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTHSPFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTHSPMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTHSPJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
14:51 EDTARWArrow Electronics to offer Hittite Microwave product line
Subscribe for More Information
08:21 EDTHSPMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
December 5, 2014
09:41 EDTXUERumor: Xueda Education strength attributed to takeover speculation

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use